NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection

Author： Herbst D Alan   Reddy K Rajender  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.10, 2013-10, pp. : 1337-1346

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A

By  

Current Medicinal Chemistry, Vol. 21, Iss. 12, 2014-04 ,pp. : 1391-1404

Bentham Science Publishers

Access to resources Recommend Favorite

A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ravidasvir

By  

Current Drug Discovery Technologies, Vol. 15, Iss. 1, 2018-04 ,pp. : 24-31

Bentham Science Publishers

Access to resources Recommend Favorite

New Non-Nucleocide NS5B Protein Inhibitors for the Treatment of Chronic Hepatitis C Infection

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 12, 2016-03 ,pp. : 1392-1401

Bentham Science Publishers

Access to resources Recommend Favorite

ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

By  

Current Medicinal Chemistry, Vol. 21, Iss. 28, 2014-09 ,pp. : 3261-3270

Bentham Science Publishers

Access to resources Recommend Favorite

Telaprevir: A Promising Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

By  

Current Medicinal Chemistry, Vol. 16, Iss. 9, 2009-03 ,pp. : 1115-1121

Bentham Science Publishers

Access to resources Recommend Favorite